EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients

Agnieszka Gorecka-Mazur iD, Anna Krygowska-Wajs, Agata Furgala, Jiaqi Li, Benjamin Misselwitz, Wojciech Pietraszko, Borys Kwinta, Bahtiyar Yilmaz iD

Neurogastroenterology & Motility · 2024-08 · 36 (8)

DOI: 10.1111/nmo.14846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 14.06.2024. Verfasst von Agnieszka Gorecka-Mazur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, Jagiellonian University, Collegium Medicum, Kraków, Poland. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome, Deep Brain Stimulation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The gut microbiota has been implicated in Parkinson's disease (PD), with alterations observed in microbial composition and reduced microbial species richness, which may influence gastrointestinal symptoms in PD patients. It remains to be determined whether the severity of gastrointestinal symptoms correlates with microbiota variations in PD patients treated pharmacologically or with subthalamic nucleus deep brain stimulation (STN‐DBS) therapy. This study aims to explore how these treatments affect gut microbiota and gastrointestinal symptoms in PD, identifying specific microbial differences associated with each treatment modality.

Methods

A total of 42 individuals diagnosed with PD, along with 38 age‐matched household control participants, contributed stool samples for microbiota characterization. Differences in the gut microbiota across various groups of PD patients and their households were identified through comprehensive sequencing of the 16S rRNA gene amplicon sequencing. Key Results Differences in microbial communities were observed between PD patients and controls, as well as between PD patients receiving pharmacological treatment and those with STN‐DBS. Pharmacologically treated advanced PD patients have higher gastrointestinal dysfunctions. Gut microbiota profile linked to STN‐DBS and reduced levodopa consumption, characterized by its anti‐inflammatory properties, might play a role in diminishing gastrointestinal dysfunction relative to only pharmacological treatments. Conclusions & Inferences Advanced PD patients on medication exhibit more gastrointestinal issues, despite relatively stable microbial diversity, indicating a complex interaction between gut microbiota, PD progression, and treatment effects. An imbalanced gut–brain axis, particularly due to reduced butyrate production, may lead to constipation by affecting the enteric nervous system, which emphasizes the need to incorporate gut microbiome insights into treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseGastrointestinal MicrobiomeDeep Brain StimulationHumansMaleFemaleMiddle AgedAgedAntiparkinson AgentsLevodopaGastrointestinal DiseasesSubthalamic Nucleus

Stichwörter der Autor:innen

Parkinson's diseasegut microbiotalevodopasurgical management

Substanzen

Antiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Department of Pathophysiology, Jagiellonian University, Collegium Medicum, Kraków, Poland.
  • Department of Neurology, Medical College, Jagiellonian University, Kraków, Poland.
  • Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Maurice Müller Laboratories, Department for Biomedical Research, University of Bern, Bern, Switzerland.
  • Department of Neurosurgery and Neurotraumatology, Medical College, Jagiellonian University, Kraków, Poland.

ORCID-Profile: Agnieszka Gorecka-Mazur, Bahtiyar Yilmaz

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Narodowe Centrum Nauki

Zitieren

APA

Gorecka-Mazur, A., Krygowska-Wajs, A., Furgala, A., Li, J., Misselwitz, B., Pietraszko, W., Kwinta, B., & Yilmaz, B. (2024). Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients. Neurogastroenterology & Motility, 36(8). https://doi.org/10.1111/nmo.14846

Vancouver

Gorecka-Mazur A, Krygowska-Wajs A, Furgala A, Li J, Misselwitz B, Pietraszko W, et al. Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients. Neurogastroenterology & Motility. 2024;36(8). doi:10.1111/nmo.14846

BibTeX
@article{GoreckaMazur2024,
  author = {Gorecka-Mazur, Agnieszka and Krygowska-Wajs, Anna and Furgala, Agata and Li, Jiaqi and Misselwitz, Benjamin and Pietraszko, Wojciech and Kwinta, Borys and Yilmaz, Bahtiyar},
  title = {Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients},
  journal = {Neurogastroenterology & Motility},
  year = {2024},
  volume = {36},
  number = {8},
  doi = {10.1111/nmo.14846}
}
Kostenlos starten →